Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Silence Therapeutics (SLN) Operating Margin: 2020-2025

Historic Operating Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -16,505.66%.

  • Silence Therapeutics' Operating Margin fell 1450319.00% to -16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -321.21%, marking a year-over-year increase of 4512.00%. This contributed to the annual value of -146.38% for FY2024, which is 5709.00% up from last year.
  • Per Silence Therapeutics' latest filing, its Operating Margin stood at -16,505.66% for Q3 2025, which was down 54.29% from -10,697.77% recorded in Q2 2025.
  • Silence Therapeutics' 5-year Operating Margin high stood at -17.20% for Q4 2024, and its period low was -20,006.34% during Q1 2025.
  • Its 3-year average for Operating Margin is -4,868.51%, with a median of -633.59% in 2023.
  • Its Operating Margin has fluctuated over the past 5 years, first surged by 61,639bps in 2024, then slumped by 1,997,079bps in 2025.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Operating Margin stood at -329.91% in 2021, then skyrocketed by 9,987bps to -230.03% in 2022, then plummeted by 40,356bps to -633.59% in 2023, then surged by 61,639bps to -17.20% in 2024, then slumped by 1,450,319bps to -16,505.66% in 2025.
  • Its Operating Margin was -16,505.66% in Q3 2025, compared to -10,697.77% in Q2 2025 and -20,006.34% in Q1 2025.